The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy

PharmacoEconomics

Volumn 21, Issue 8, 2003, Pages 573-585

  Nordmann, Alain J ^a,b,c   Krahn, Murray ^a,d   Logan, Alexander G ^b   Naglie, Gary ^a,d   Detsky, Allan S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; INDAPAMIDE; LISINOPRIL; LOSARTAN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CALCULATION; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEALTH CARE COST; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; META ANALYSIS; MONEY; PRIORITY JOURNAL; PURCHASING; QUALITY OF LIFE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CANADA; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIURETICS; DRUG UTILIZATION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MARKOV CHAINS; PRACTICE GUIDELINES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS;

EID: 0038171279     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321080-00004     Document Type: Article

References (58)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-45
2. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines subcommittee. J Hypertens 1999; 17: 151-83
3. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of Blood Pressure. JAMA 1997; 278: 1745-8
4. Bourgault C, Rainville B, Suissa S. Antihypertensive drug therapy in Saskatchewan: patterns and determinants in hypertension. Arch Intern Med 2001; 161: 1873-9
5. Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160: 31-7
6. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 1-11
7. Hansson L, Lindholm LH, Niskanen L, for the Captopril Prevention Project (CAPPP) study group, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6
8. Hansson L, Lindholm LH, Ekbom T, et al. , for the STOP-Hypertension-2 study group. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6
9. Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-6
10. Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13: 564-9
11. Okano GJ, Rascati KL, Wilson JP, et al. A comparison of antihypertensive medication utilization before and after guideline changes using the Department of Defense Prescription Database. Ann Pharmacother 1999; 33: 548-53
12. Guidry UC, Evans JC, Larson MG, et al. Temporal trends in event rates after Q-wave myocardial infarction. The Framingham Heart Study. Circulation 1999; 100: 2054-9
13. Ho KKL, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-15
14. Dennis MS, Burn JPS, Sandercock PAG, et al. Long-term survival after first-ever stroke: the Oxfordshire community stroke project. Stroke 1993; 24: 796-800
15. Adams KF, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996; 28: 1781-8
16. Swedberg K, Kjekshust J, Snappin S, for the CONSENSUS investigators. Long-term survival in severe heart failure in patients treated with enalapril: ten year follow-up of CONSENSUS I. Eur Heart J 1999; 20: 136-9
17. Detailed life table, Canada, 1990-92, Cat. No. 84-537, Statistics Canada. Available from URL: http://www.statcan.ca/english/freepub/84-537-XIE/tables.htm [Accessed 2003 April 15]
18. Naimark D, Krahn MD, Naglie G, et al. Primer on medical decision analysis: part 5, working with Markov processes. Med Decis Making 1997; 17: 152-9
19. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
20. Consumer price index, 1996 classification, annual average indexes, Canada and provinces. Statistics Canada [online]. Available from URL: http://www.statcan.ca/english/Pgdb/Economy/Economic/econ09a.htm [Accessed 2003 Apr 16]
21. Purchasing power parities and real expenditures: United States/Canada - updates, 1992-2001. Available from URL: http://www.statcan.ca/cgi-bin/downpub/listpub.cgi?catno=13-604-MIB2002039 [Accessed 2003 Apr 17]
22. Fletcher AE, Bulpitt CS, Hawkins CM, et al. Quality of life on antihyperensive therapy: a randomized double-blind controlled trial of captopril and atenolol. J Hypertens 1990; 8: 463-6
23. Palmer AJ, Fletcher AE, Rudge PJ, et al. Quality of life in hypertensives treated with atenolol or captopril: a double-blinded crossover trial. J Hypertens 1992; 10: 1409-16
24. Tingleff J, Munch M, Jakobsen TJ, et al. Prevalence of left ventricular hypertrophy in a hypertensive population. Eur Heart J 1996; 17: 143-9
25. Levy D, Garrison RJ, Savage DS, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6
26. Schillaci G, Verdecchia P, Borgioni C, et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol 1994; 74: 714-9
27. Cupples LA, Gagnon DR, Wong ND, et al. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: The Framingham Study. Am Heart J 1993; 125: 863-72
28. Sacco RL, Wolf PA, Kannel WB, et al. Survival and recurrence following stroke. The Framingham Study. Stroke 1982; 13: 290-5
29. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62
30. Lampe FC, Whincup PH, Wannamethee SG, et al. The natural history of prevalent ischemic heart disease in middle-aged men. Eur Heart J 2000; 21: 1052-62
31. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628-37
32. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983; 75: 4-11
33. Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol 1987; 60: 85I-93I
34. Gosse P, Sheridan DJ, Zannad F, et al. , on behalf of the LIVE Investigators.Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000, 75
35. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOHMS). Circulation 1995; 91: 698-706
36. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents: The Department of Veterans Affair Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95: 2007-14
37. Hammond IW, Devereux RB, Alderman MH, et al. The prevalence and correlates of left ventricular hypertrophy among employed persons with uncomplicated hypertension. J Am Coll Cardiol 1986; 7: 639-50
38. Levy D, Savage DD, Garrison RJ, et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 59: 956-60
39. Rosengren A, Wilhelmsen L, Hagman M, et al. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16 year follow-up of the primary prevention study, Göteborg, Sweden. J Intern Med 1998; 244: 495-505
40. Wolf PA, D'Agostino RB, O'Neal A, et al. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke 1992; 23: 1551-5
41. Nease RF, Kneeland T, O'Connor GT, for the Ischemic Heart Disease Patient Outcomes Research Team, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. JAMA 1995; 273: 1185-90
42. Naglie G, Tansey C, Llewellyn-Thomas H, et al. Senior's preferences for chronic health states: utility assessments of heart disease, stroke and cognitive impairment [abstract]. Med Decis Making 1997; 157: 521
43. Shin AY, Porter PJ, Wallace MC, et al. Quality of life of stroke in younger individuals: utility assessment in patients with arteriovenous malformations. Stroke 1997; 28: 2395-9
44. Fryback DG, Dasbach EJ, Klein T, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102
45. Fee Schedule of the Ministry of Health in Ontario: Schedule of benefits: physician services under the Health Insurance Act. 2000 May 1
46. Drug Benefit Formulary of the Ministry of Health of Ontario No. 36, 1998
47. O'Brien B, Willan A, Blackhouse G, et al. Will the use of low-molecular weight heparin (enoxaparin) in patients with acute coronary syndromes save costs in Canada? Am Heart J 2000; 139: 423-9
48. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998; 81: 1110-5
49. Chan B, Hayes B. Cost of stroke in Ontario, 1994/95. CMAJ 1998; 159 Suppl. 6: S2-7
50. Taylor TN, Davis PH, Torner JC, et al. Lifetime costs of stroke in the United States. Stroke 1996; 27: 1459-66
51. Delea TE, Vera-Llonch M, Richner RE, et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999; 83: 890-6
52. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-81
53. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53
54. Wing LMH, Reid CM, Ryan P, for the Second Australian National Blood Pressure Study Group, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-92
55. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-97
56. Dahlöf B, Devereux B, Kjeldsen SE, for the LIFE study group, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003
57. Lewis EJ, Hunsicker LG, Bain RP, for the Collaborative Study Group, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
58. Gosse P, Julien V, Jarnier P, et al. Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? J Hum Hypertens 1999; 13: 505-9